Kızılırmak Ayse Sezgi, Karadibak Didem, Gultekin Sukriye Cansu, Ozsoy Ismail, Yavuzsen Husnu Tore, Yavuzsen Tugba, Oztop Ilhan
Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Democracy University, Izmir, Turkey.
Department of Cardiopulmonary Physiotherapy-Rehabilitation, Faculty of Physical Therapy and Rehabilitation, Dokuz Eylul University, Izmir, Turkey.
Support Care Cancer. 2023 Apr 5;31(4):248. doi: 10.1007/s00520-023-07706-6.
To identify the predictors of the 6-min walk test (6MWT) and investigate the relationship between 6MWT, performance status, functional mobility, fatigue, quality of life, neuropathy, physical activity level, and peripheral muscle strength in patients with ovarian cancer (OC).
Twenty-four patients diagnosed with stage II-III ovarian cancer were included in the study. Patients were assessed using the following measurement methods: 6MWT for walking capacity, Eastern Cooperative Oncology Group Performance Scale (ECOG-PS) for performance status, an armband physical activity monitor for physical activity level, Checklist Individual Strength (CIS) for fatigue, Functional Cancer Treatment Evaluation with Quality of Life-Extreme (FACT-O) for quality of life, Functional Evaluation of Cancer Treatment/Gynecological Oncology-Neurotoxicity (FACT/GOG-NTX) for neuropathy, a hand-held dynamometer for peripheral muscle strength, and 30-s chair-stand test for functional mobility.
The mean 6MWT distance was 578.48 ± 115.33 meters. 6MWT distance correlated with ECOG-PS score (r = -0.438, p = 0.032), handgrip strength (r = 0.452, p= 0030), METs (r = 0.414, p = 0.044) 30s-CST (r= 0.417, p= 0.043), and neuropathy score (r = 0.417, p = 0.043) significantly. There was no relationship between 6MWT distance and other parameters (p> 0.05). Multiple linear regression analysis demonstrated that performance status was the sole predictor of 6MWT.
The walking capacity seems to be associated with performance status, peripheral muscle strength, level of physical activity, functional mobility, and severity of neuropathy in patients with ovarian cancer. Evaluating these may help clinicians to understand factors behind the decreased walking capacity.
确定6分钟步行试验（6MWT）的预测因素，并研究6MWT与卵巢癌（OC）患者的体能状态、功能活动能力、疲劳、生活质量、神经病变、身体活动水平及外周肌肉力量之间的关系。
本研究纳入了24例诊断为II-III期卵巢癌的患者。采用以下测量方法对患者进行评估：用6MWT评估步行能力，用东部肿瘤协作组体能状态量表（ECOG-PS）评估体能状态，用臂带式身体活动监测仪评估身体活动水平，用简易个体力量检查表（CIS）评估疲劳，用癌症治疗功能评价量表-生活质量量表（FACT-O）评估生活质量，用癌症治疗功能评价量表/妇科肿瘤神经毒性量表（FACT/GOG-NTX）评估神经病变，用握力计评估外周肌肉力量，用30秒坐立试验评估功能活动能力。
6MWT的平均距离为578.48±115.33米。6MWT距离与ECOG-PS评分（r = -0.438，p = 0.032）、握力（r = 0.452，p = 0.030）、代谢当量（r = 0.414，p = 0.044）、30秒坐立试验（r = 0.417，p = 0.043）及神经病变评分（r = 0.417，p = 0.043）显著相关。6MWT距离与其他参数之间无相关性（p>0.05）。多元线性回归分析表明，体能状态是6MWT的唯一预测因素。
卵巢癌患者的步行能力似乎与体能状态、外周肌肉力量、身体活动水平、功能活动能力及神经病变严重程度有关。评估这些因素可能有助于临床医生了解步行能力下降背后的因素。
